Literature DB >> 20022058

Ethylene glycol induced hyperoxaluria increases plasma and renal tissue asymmetrical dimethylarginine in rats: a new pathogenetic link in hyperoxaluria induced disorders.

Hasan Aydin1, Faruk Yencilek, Nilgün Mutlu, Nil Comunoğlu, Hasbey Hakan Koyuncu, Kemal Sarica.   

Abstract

PURPOSE: The pathogenesis of kidney stones remains elusive. There is some evidence that hyperoxaluria may effect vascular endothelium and many studies link renal stones to atherosclerosis. Also, renal vascular endothelial cells regulate proximal tubular epithelial cell function. We determined the effect of hyperoxaluria on plasma and tissue levels of asymmetrical dimethylarginine. The secondary aim was to determine the effect of verapamil on asymmetrical dimethylarginine.
MATERIALS AND METHODS: A total of 42 Sprague-Dawley rats were included in the study. In groups 1A, 1B and 1C hyperoxaluria was induced with ethylene glycol for 2 weeks. Groups 2A, 2B and 2C received ethylene glycol for 14 days and verapamil for 28 days. Control group 3 received no specific medication but distilled water. Blood samples were obtained at 24 hours and at study end, and kidney samples were obtained at 24 hours, and 7 and 28 days for histopathological evaluation.
RESULTS: Plasma asymmetrical dimethylarginine increased early in the hyperoxaluric group (p = 0.0002). The effect was retained at the end of the study period (p = 0.01). There was no increase in asymmetrical dimethylarginine in the verapamil group on short-term and long-term followup. Hyperoxaluria induced a significantly dense staining pattern in renal tissue asymmetrical dimethylarginine vs controls (p = 0.01). Asymmetrical dimethylarginine staining did not differ in the control and verapamil groups.
CONCLUSIONS: Increased systemic and local tissue asymmetrical dimethylarginine may help explain the pathogenetic mechanisms of hyperoxaluria induced disorders such as nephrolithiasis and atherosclerosis. Copyright 2010 American Urological Association. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20022058     DOI: 10.1016/j.juro.2009.09.076

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  6 in total

1.  Systemic endothelial function measured by flow-mediated dilation is impaired in patients with urolithiasis.

Authors:  Esin Yencilek; Hakan Sarı; Faruk Yencilek; Ezgi Yeşil; Hasan Aydın
Journal:  Urolithiasis       Date:  2016-11-23       Impact factor: 3.436

2.  Human umbilical vein endothelial cells accelerate oxalate-induced apoptosis of human renal proximal tubule epithelial cells in co-culture system which is prevented by pyrrolidine dithiocarbamate.

Authors:  Kemal Sarıca; Hasan Aydin; Faruk Yencilek; Dilek Telci; Bayram Yilmaz
Journal:  Urol Res       Date:  2012-01-06

3.  Potential Mechanisms Responsible for the Antinephrolithic Effects of an Aqueous Extract of Fructus Aurantii.

Authors:  Xiaoran Li; Qiang Liang; Yunji Sun; Long Diao; Ze Qin; Wei Wang; Jianzhong Lu; Shengjun Fu; Baoliang Ma; Zhongjin Yue
Journal:  Evid Based Complement Alternat Med       Date:  2015-06-15       Impact factor: 2.629

4.  Hyperoxaluria Induces Endothelial Dysfunction in Preglomerular Arteries: Involvement of Oxidative Stress.

Authors:  Javier Saenz-Medina; Mercedes Muñoz; Claudia Rodriguez; Cristina Contreras; Ana Sánchez; María José Coronado; Elvira Ramil; Martin Santos; Joaquín Carballido; Dolores Prieto
Journal:  Cells       Date:  2022-07-27       Impact factor: 7.666

5.  Urolithiasis Develops Endothelial Dysfunction as a Clinical Feature.

Authors:  Javier Sáenz-Medina; María Martinez; Silvia Rosado; Manuel Durán; Dolores Prieto; Joaquín Carballido
Journal:  Antioxidants (Basel)       Date:  2021-05-04

Review 6.  Endothelial Dysfunction: An Intermediate Clinical Feature between Urolithiasis and Cardiovascular Diseases.

Authors:  Javier Saenz-Medina; Mercedes Muñoz; Claudia Rodriguez; Ana Sanchez; Cristina Contreras; Joaquín Carballido-Rodríguez; Dolores Prieto
Journal:  Int J Mol Sci       Date:  2022-01-14       Impact factor: 5.923

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.